Skip to main navigation Skip to search Skip to main content

Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATETM Study

  • Christian Buske
  • , Alessandra Tedeschi
  • , Judith Trotman
  • , Ramón García-Sanz
  • , David MacDonald
  • , Veronique Leblond
  • , Béatrice Mahé
  • , Charles Herbaux
  • , Jeffrey V. Matous
  • , Constantine S. Tam
  • , Leonard T. Heffner
  • , Marzia Varettoni
  • , M. Lia Palomba
  • , Chaim Shustik
  • , Efstathios Kastritis
  • , Steven P. Treon
  • , Jerry Ping
  • , Bernhard Hauns
  • , Israel Arango-Hisijara
  • , Meletios A Dimopoulos
  • University of Ulm
  • ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • University of Sydney
  • Hospital Universitario de Salamanca, Salamanca, Spain
  • University of Ottawa
  • University of Paris
  • Centre Hospitalier Universitaire de Nantes, Nantes, France.
  • Centre Hospitalier Régional Universitaire de Lille, Institute of Hematolog-Tranfusion, Lille, France
  • Colorado Blood Cancer Institute, Denver, CO
  • Peter MacCallum Cancer Centre
  • Emory University
  • University of Pavia
  • Memorial Sloan-Kettering Cancer Center
  • McGill University Health Centre
  • National and Kapodistrian University of Athens
  • Harvard University
  • Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA.

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
JournalBlood
Volume136
DOIs
StatePublished - Nov 5 2020
Externally publishedYes

Disciplines

  • Medicine and Health Sciences
  • Gastroenterology
  • Internal Medicine

Cite this